Phaseline

Companies › Gubra

Gubra: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Metabolic and endocrine; next expected readout Dec 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
GUB-UCN2
Urocortin 2 analog
UCN2Phase 1ObesityDec 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07702890GUB-UCN2Phase 1ObesityMetabolic and endocrineDec 2028

Targets

UCN2 (1)

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.